Current Report Filing (8-k)
April 30 2020 - 5:22PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): April 24, 2020
AgeX
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-38519
|
|
82-1436829
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
965
Atlantic Avenue
Suite
101
Alameda,
California 94501
(Address
of principal executive offices)
(510)
671-8370
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
AGE
|
|
NYSE
American
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Forward-Looking
Statements
Any
statements that are not historical fact (including, but not limited to statements that contain words such as “may,”
“will,” “believes,” “plans,” “intends,” “anticipates,” “expects,”
“estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual
results to differ materially from the results anticipated in these forward-looking statements are contained in AgeX’s periodic
reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and other filings that
AgeX may make with the SEC. Undue reliance should not be placed on these forward-looking statements which speak only as of the
date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, AgeX disclaims
any intent or obligation to update these forward-looking statements.
References
in this Report to “AgeX,” “we” or “us” refer to AgeX Therapeutics, Inc.
Item
2.05 Costs Associated with Exit or Disposal Activities.
Based
on a strategic review of its operations, giving consideration to the status of its product development programs, human resources,
capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have
made certain adjustments to AgeX’s operating plans and budgets to reduce its projected cash expenditures to extend the period
over which AgeX can continue its operations with its available cash resources.
AgeX
has pursued a dual business strategy to diversify risk and maximize opportunities. AgeX’s licensing and collaboration strategy
is based on its two primary technology platforms, UniverCyte™ immunotolerance technology, and PureStem™ cell derivation
and manufacturing technology. Since the launch of its licensing and collaboration strategy in January 2020, AgeX delivered a research
collaboration in Japan focused on developing universally transplantable cells for therapeutic use based on UniverCyte™,
and entered into a neural stem cell therapy research collaboration for neurological disorders utilizing PureStem™
at a California state university. AgeX has also pursued its in-house product development strategy focused primarily on two cell
therapy products, VASC1 for tissue ischemia, and BAT1 for metabolic disorders such as type II diabetes. AgeX also plans development
of iTR (induced tissue regeneration) technology.
On
April 24, 2020, AgeX’s Board of Directors determined to initiate employee lay-offs designed to balance those objectives
with its current cash resources, optimization of human resources, and conditions in the capital markets resulting from the COVID-19
pandemic. The reduction in staffing is anticipated to affect 12 employees, primarily research and development personnel, and
is expected to be completed on or around May 1, 2020. AgeX expects to pay approximately $105,000 in accrued payroll and
unused paid time off and other benefits and expects to recognize approximately $194,800 in restructuring charges in connection
with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all
of which are expected to be settled in cash.
These
budgetary and personnel adjustments will result in the deferral of in-house work on the development of AgeX therapy product candidates
and its iTR technology, and may also lead to outsourcing of some of that work, until further funding, whether by financing or
research grants, can be obtained to rebuild a research and development staff for one or more of those programs. Development of
AgeX’s iTR technology may be done at AgeX’s subsidiary Reverse Bioengineering, Inc. subject to successful financing
of the subsidiary.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AGEX
THERAPEUTICS, INC.
|
|
|
|
Date:
April 30, 2020
|
By:
|
/s/
Russell Skibsted
|
|
|
Chief
Financial Officer
|
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Apr 2023 to Apr 2024